| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/26/2002 | WO2002075025A2 Process for preparing low defect density silicon using high growth rates |
| 09/26/2002 | WO2002074981A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 09/26/2002 | WO2002074970A1 A process for the production of an inhibitor of human platelet aggregation and soybean lipoxygenase |
| 09/26/2002 | WO2002074945A1 Method for cleaving human growth hormone gh |
| 09/26/2002 | WO2002074922A2 Compositions and methods for modulating an immune response |
| 09/26/2002 | WO2002074910A2 Selective anti-viral nucleoside chain terminators |
| 09/26/2002 | WO2002074835A1 Process for producing lactic acid oligomer |
| 09/26/2002 | WO2002074798A2 The genome of a bifidobacterium |
| 09/26/2002 | WO2002074792A1 Fo-6979 substances and process for producing the same |
| 09/26/2002 | WO2002074784A2 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain |
| 09/26/2002 | WO2002074781A1 Process for preparing n6-substituted aminopurine ribofuranose nucleosides |
| 09/26/2002 | WO2002074780A1 Chemical compounds |
| 09/26/2002 | WO2002074777A2 Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity |
| 09/26/2002 | WO2002074776A2 Highly purified and crystalline form of harringtonine |
| 09/26/2002 | WO2002074774A1 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors |
| 09/26/2002 | WO2002074773A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 09/26/2002 | WO2002074772A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 09/26/2002 | WO2002074771A1 Tricyclic heterocyclic compound, process for producing the same, and use |
| 09/26/2002 | WO2002074770A1 Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient |
| 09/26/2002 | WO2002074769A1 Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| 09/26/2002 | WO2002074768A1 Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) |
| 09/26/2002 | WO2002074767A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074766A1 Method of preparing lansoprazole and its intermediate |
| 09/26/2002 | WO2002074765A1 Phenyl derivatives 3 |
| 09/26/2002 | WO2002074764A2 Piperazine derivatives and their use as 5-ht1b ligands |
| 09/26/2002 | WO2002074763A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | WO2002074759A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
| 09/26/2002 | WO2002074758A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | WO2002074756A2 Urokinase inhibitors |
| 09/26/2002 | WO2002074754A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 09/26/2002 | WO2002074752A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074751A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074750A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074749A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074748A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074747A1 Farnesyltransferase inhibitors |
| 09/26/2002 | WO2002074746A1 Benzazepine derivatives |
| 09/26/2002 | WO2002074743A1 Aryl-substituted alicyclic compound and medical composition comprising the same |
| 09/26/2002 | WO2002074742A2 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 09/26/2002 | WO2002074741A1 Pyrrolidine ester derivatives with oxytocin modulating acitvity |
| 09/26/2002 | WO2002074740A1 Biguanide derivatives |
| 09/26/2002 | WO2002074736A1 New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition |
| 09/26/2002 | WO2002074735A2 Biurethane derivatives |
| 09/26/2002 | WO2002074733A2 Tryptase-inhibitors |
| 09/26/2002 | WO2002074730A1 INHIBITORS OF INTEGRIN αvβ¿6? |
| 09/26/2002 | WO2002074726A2 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | WO2002074725A1 Novel ligands of nuclear receptor superfamily, process for producing the same and use thereof |
| 09/26/2002 | WO2002074719A2 Inhibitors of plasmepsins |
| 09/26/2002 | WO2002074388A1 Bisarylamines as potassium channel openers |
| 09/26/2002 | WO2002074348A1 Dry powder compositions comprising labelled particles for inhalation |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074343A2 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body |
| 09/26/2002 | WO2002074342A1 Remedies for arteriosclerosis |
| 09/26/2002 | WO2002074341A1 Antipruritics |
| 09/26/2002 | WO2002074340A1 Process for producing sustained release preparation |
| 09/26/2002 | WO2002074329A1 Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process |
| 09/26/2002 | WO2002074328A1 Methods of treating respiratory conditions |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074321A1 Composition comprising cocoa and a dopamine d2 receptor agonist |
| 09/26/2002 | WO2002074320A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity |
| 09/26/2002 | WO2002074319A1 Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases |
| 09/26/2002 | WO2002074318A1 Il-12 expression controlling agents |
| 09/26/2002 | WO2002074317A1 Process for producing wet ribavirin pellets |
| 09/26/2002 | WO2002074316A1 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| 09/26/2002 | WO2002074315A1 Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy |
| 09/26/2002 | WO2002074314A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| 09/26/2002 | WO2002074313A1 Drugs containing reduced vitamin b¿2? |
| 09/26/2002 | WO2002074312A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | WO2002074311A1 Antitumoral, antiviral, antibacterial, antiparasitic, anti-inflammatory, immunomodulatory and antimicotic medicinal preparation, method for production and dosage forms thereof |
| 09/26/2002 | WO2002074310A2 Stabilized formulation of selective ligands of retinoic acid gamma-receptors |
| 09/26/2002 | WO2002074309A2 Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors |
| 09/26/2002 | WO2002074308A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 09/26/2002 | WO2002074307A1 Treatment of restenosis |
| 09/26/2002 | WO2002074305A1 Use of a substantially cell membrane impermeable compound for treating arthritis |
| 09/26/2002 | WO2002074303A1 Amino acid compositions for ameliorating kidney failure |
| 09/26/2002 | WO2002074302A1 Amino acid compositions for ameliorating liver failure |
| 09/26/2002 | WO2002074301A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 09/26/2002 | WO2002074300A1 Composition for treating arteriosclerosis comprising 3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid or its derivatives |
| 09/26/2002 | WO2002074299A1 TNFα PRODUCTION INHIBITORS |
| 09/26/2002 | WO2002074298A1 Il-6 production inhibitors |
| 09/26/2002 | WO2002074297A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| 09/26/2002 | WO2002074296A1 Remedies for solid cancer containing hydroxamic acid derivatives as the active ingredient |
| 09/26/2002 | WO2002074295A1 A composition for the prophylaxis or treatment of senile dementia |
| 09/26/2002 | WO2002074294A1 Taurine compounds |
| 09/26/2002 | WO2002074293A2 Methods for restoring cognitive function following systemic stress |
| 09/26/2002 | WO2002074292A2 Hormone replacement therapy |
| 09/26/2002 | WO2002074291A2 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor |
| 09/26/2002 | WO2002074290A2 Dermatological preparations containing a nsaid |
| 09/26/2002 | WO2002074289A2 Antitumor compositions containing taxane derivatives |
| 09/26/2002 | WO2002074288A2 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide |
| 09/26/2002 | WO2002074287A2 Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics |
| 09/26/2002 | WO2002074286A1 Transdermal patch for administering fentanyl |
| 09/26/2002 | WO2002074285A1 Controlled release sulfonylurea formulation |
| 09/26/2002 | WO2002074282A1 New composition |
| 09/26/2002 | WO2002074281A1 Ophthalmic compositions and use thereof |
| 09/26/2002 | WO2002074278A1 Topical composition containing an association of avocado furane lipids and isoflavones |
| 09/26/2002 | WO2002074275A2 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces |
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074246A2 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 09/26/2002 | WO2002074242A2 Inhibition of toxoplasma gondii) replication by pyridinylimidazoles |